An interventional study of hypovolemic phlebotomy in Hepatocellular Carcinoma, sponsored by The First Affiliated Hospital with Nanjing Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by The First Affiliated Hospital with Nanjing Medical University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,314 studies in Carcinoma, Hepatocellular with a site in China — 489 open to participants now, 561 under way, 70 of them phase 3. Carcinoma, Hepatocellular · China.
Among the 1,314 studies in Carcinoma, Hepatocellular with a site in China, this one is the 318th largest by planned enrollment of the 1,038 interventional ones that give a count, is one of 111 that started in 2022, is one of 236 with no phase, reaches primary completion later than 255 of the 560 other live ones, and was the 803rd registered.
3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.
Browse Carcinoma, Hepatocellular studies →489 of the 1,314 studies in Carcinoma, Hepatocellular with a site in China are open now. Recruiting first, the newest first:
Acepodia Biotech, Inc. · Sites in China
Ages 18–75
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Sites in China
Ages 18+
Sun Yat-sen University · Sites in China
Ages 18–75
Sun Yat-sen University · Sites in China
Ages 18–70
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,314 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 228 · Phase 2 456 · Phase 3 203 · Phase 4 38
First in 1983; this study’s year is marked. 111 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 160 is above the median of 53 across 2,623 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 77 across the 1,038 interventional studies, 300 across the 275 observational. Of the 329 that completed or were terminated, 49 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
235 of 1,314 have an industry lead sponsor. The 10 most frequent:
The First Affiliated Hospital with Nanjing Medical University is the lead sponsor of 569 studies on the registry; 317 are open to participants now.
The First Affiliated Hospital with Nanjing Medical University has 9 studies filed under Carcinoma, Hepatocellular — fewer than ten, so there is no comparison to draw.
130 of the studies in Carcinoma, Hepatocellular with a site in China that are under way reach primary completion within a year, 15 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03368651Phase 3Sun Yat-sen UniversityThe Impact on Survival of Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) Who Underwent Hepatectomy : A Random, Controlled, Stage III Clinical Trial. | 2026-11-30 |
| NCT04344158Phase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC) | 2026-12 |
| NCT05062837Phase 3Guangxi Medical UniversityHepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC | 2026-12-30 |
| NCT03859128Phase 3Shanghai Junshi Bioscience Co., Ltd.Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical Resection | 2026-12-31 |
| NCT04523493Phase 3Shanghai Junshi Bioscience Co., Ltd.Phase III Study of Toripalimab(JS001) Combined With Lenvatinib for Advanced HCC | 2026-12-31 |
Add all 130 to your calendar (.ics) → With an account.
Among the 1,314 studies in Carcinoma, Hepatocellular with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn about goal-directed LCVP based on hypovolemic phlebotomy (HP) in laparoscopic hepatectomy. The main questions it aims to answer are:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
patients in this group undergoing laparoscopic hepatectomy was performed with goal-directed LCVP based on hypovolemic phlebotomy (HP)
Procedure: hypovolemic phlebotomy
patients in this group undergoing laparoscopic hepatectomy was performed with LCVP but no hypovolemic phlebotomy (HP)
hypovolemic phlebotomy was performed after induction of anesthesia and before the star of parenchymal division, with a goal-directed low central venous pressure drop to 5mmHg.
Also known as: HP
The proportion of allogeneic red blood cell products transfusion
The primary end point of the study was the proportion of patients who required transfusion of allogeneic red blood cell products during laparoscopic hepatectomy or at any time during the hospitalization during the index admission.
Time frame: From date of operation until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 12 months.
The volume of Phlebotomy
Time frame: From the start of operation until the end of operation.
The volume of Intraoperative blood loss
Time frame: From the start of operation until the end of operation (during the operation).
The volume of Allogeneic transfusion (perioperative)
Time frame: From date of operation until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 12 months.
The volume of Allogeneic transfusion (postoperative)
Time frame: From the end of operation until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 12 months.
The volume of Allogeneic transfusion (intraoperative)
Time frame: From the start of operation until the end of operation.
The volume of Fresh frozen plasm (FFP) transfusion
Time frame: From date of operation until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 12 months.
The volume of Platelets transfusion
Time frame: From date of operation until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 12 months.
The volume of Albumin transfusion
Time frame: From date of operation until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 12 months.
Perioperative lowest concentration of Hb
Time frame: From the start of operation until the date of discharge from hospital or date of death from any cause, whichever came first. assessed up to 12 months.
Pre-transection central venous pressure (CVP), (basic CVP)
Time frame: From the start of anesthesia induction until the star of operation.
Lowest central venous pressure (CVP)
Time frame: From the start of operation until the end of operation (during the operation).
time of pringle maneuver
Time frame: From the start of operation until the end of operation.
number of pringle maneuver
how many patients have the pringle maneuver
Time frame: From the start of operation until the end of operation.
operating time
Time frame: From the start of operation until the end of operation.
The proportion of laparoscopic hepatectomy converted to open liver resection
Time frame: From the start of operation until the end of operation.
Length of stay
Time frame: From date of hospitalization until the date of discharge from hospital or date of death from any cause, whichever came first. assessed up to 12 months
Number of Participants with postoperative complications (overall)
Time frame: From date of operation until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 1 months.
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from May 2022 to primary completion in Aug 2026, 51 months.
Of 361 non-industry interventional studies with no phase under Carcinoma, Hepatocellular, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 76. This study's 51 months is close to that.
Counting every sponsor, half of 385 studies reached it within 47 months; a quarter within 23 and three quarters within 75.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Jan 2026 → Aug 2026 and completion May 2026 → Dec 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The First Affiliated Hospital with Nanjing Medical University →